CAMBRIDGE, Mass., Sept. 22, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.
The poster, entitled "A Phase 1 study of IPI-926, an inhibitor of the Hedgehog pathway, in patients with advanced or metastatic solid tumors," will be presented by Antonio Jimeno, M.D., Ph.D., Associate Professor, University of Colorado School of Medicine, during the Developmental Therapeutics session, which will take place from 12:30 – 3:30 p.m. CEST (6:30 – 9:30 a.m. EDT) on Sunday, October 10, 2010 in Yellow Hall 1.
A copy of the poster will be available on Infinity's website, www.infi.com, following its presentation.
About IPI-926 and the Hedgehog Pathway
Malignant activation of the Hedgehog pathway is responsible for a broad range of cancers through three distinct mechanisms: signaling to the tumor microenvironment; signaling to tumor progenitor cells; and genetic activation of the Hedgehog pathway in tumor cells. IPI-926, a small molecule inhibitor of the Hedgehog pathway, represents an opportunity for addressing a number of difficult-to-treat cancers by disrupting malignant activation of the pathway.
IPI-926 is currently being evaluated in a Phase 1 study in solid tumors as well as a Phase 1b/2 study in combination with Gemzar® (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer. These clinical trials build upon a robust set of supporting preclinical data that provide a strong rationale for evaluating the potential of IPI-926 for treatment of a broad range of cancers.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity's programs in the inhibition of the Hsp90 chaperone system, the Hedgehog pathway, fatty acid amide hydrolase and phosphoinositide-3-kinase are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.
Gemzar® is a registered trademark of Eli Lilly and Company.
CONTACT: Infinity Pharmaceuticals, Inc. Jaren Irene Madden 617-453-1336 Jaren.Madden@infi.com http://www.infi.com
